Hatchtech Adds $7.8M, Preps for Phase III Trial of DeOvo
By Nuala Moran
Wednesday, May 16, 2012
LONDON HatchTech Pty. Ltd. raised A$7.8 million (US$7.8 million) from existing investors, enabling it to push DeOvo, a metalloproteinase inhibitor for treating head lice, into a Phase III U.S. trial.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.